WO2011111971A3 - (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 - Google Patents

(ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 Download PDF

Info

Publication number
WO2011111971A3
WO2011111971A3 PCT/KR2011/001579 KR2011001579W WO2011111971A3 WO 2011111971 A3 WO2011111971 A3 WO 2011111971A3 KR 2011001579 W KR2011001579 W KR 2011001579W WO 2011111971 A3 WO2011111971 A3 WO 2011111971A3
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
oxazolidin
triazin
dihydro
fluoro
Prior art date
Application number
PCT/KR2011/001579
Other languages
English (en)
French (fr)
Other versions
WO2011111971A2 (ko
Inventor
조영락
백성윤
채상은
이홍범
박태교
우성호
김용주
Original Assignee
㈜레고켐바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ㈜레고켐바이오사이언스 filed Critical ㈜레고켐바이오사이언스
Priority to US13/583,492 priority Critical patent/US8703939B2/en
Priority to CN201180013805.4A priority patent/CN102803256B/zh
Publication of WO2011111971A2 publication Critical patent/WO2011111971A2/ko
Publication of WO2011111971A3 publication Critical patent/WO2011111971A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 사이클릭 아미드라존 기를 가지는 옥사졸리디논계 항생제 화합물인 (R)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1H)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체를 제조하는 방법 및 그 중간체에 관한 것으로, 출발물질로 3,4-다이플루오로-4-니트로벤젠을 사용한다. 본 발명의 제조방법에 따르면 종래 방법에 비해 간단한 방법으로 옥사졸리디논계 항생제로 유용한 화합물인 (R)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1H)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체를 고순도 및 고수율로 제조할 수 있다.
PCT/KR2011/001579 2010-03-08 2011-03-08 (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 WO2011111971A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/583,492 US8703939B2 (en) 2010-03-08 2011-03-08 Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives
CN201180013805.4A CN102803256B (zh) 2010-03-08 2011-03-08 (r)-3-(3-氟-4-(1-甲基-5,6-二氢-1,2,4-三嗪-4(1h)-基)苯基)-5-(取代甲基)恶唑烷-2-酮衍生物的制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0020525 2010-03-08
KR1020100020525A KR101128029B1 (ko) 2010-03-08 2010-03-08 (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법

Publications (2)

Publication Number Publication Date
WO2011111971A2 WO2011111971A2 (ko) 2011-09-15
WO2011111971A3 true WO2011111971A3 (ko) 2012-01-12

Family

ID=44563981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001579 WO2011111971A2 (ko) 2010-03-08 2011-03-08 (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법

Country Status (4)

Country Link
US (1) US8703939B2 (ko)
KR (1) KR101128029B1 (ko)
CN (1) CN102803256B (ko)
WO (1) WO2011111971A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702900B (zh) * 2021-08-09 2024-02-09 上海纳为生物技术有限公司 一种rmx2001制剂组合物
KR102608785B1 (ko) 2021-12-27 2023-12-04 가톨릭대학교 산학협력단 옥사졸리딘-2-온 유도체 및 이의 제조 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035648A1 (en) * 2001-10-25 2003-05-01 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
WO2004048350A2 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
WO2004056819A1 (en) * 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial agents
EP2072513A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof
EP2072514A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. 1(2)H-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2010036000A2 (en) * 2008-09-24 2010-04-01 Legochem Bioscience Ltd. Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0227704D0 (en) * 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
EP2141162A1 (en) 2008-07-01 2010-01-06 Ferrer Internacional, S.A. 3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
EP2141161A1 (en) 2008-07-01 2010-01-06 Ferrer Internacional, S.A. 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035648A1 (en) * 2001-10-25 2003-05-01 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
WO2004048350A2 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
WO2004056819A1 (en) * 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial agents
EP2072513A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof
EP2072514A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. 1(2)H-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2010036000A2 (en) * 2008-09-24 2010-04-01 Legochem Bioscience Ltd. Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
WO2011111971A2 (ko) 2011-09-15
KR101128029B1 (ko) 2012-03-29
CN102803256A (zh) 2012-11-28
KR20110101499A (ko) 2011-09-16
US8703939B2 (en) 2014-04-22
US20130005967A1 (en) 2013-01-03
CN102803256B (zh) 2015-03-18

Similar Documents

Publication Publication Date Title
IL223002A0 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
WO2013186792A3 (en) Process for preparation of azilsartan medoxomil and its salts
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2012107814A8 (en) An improved process for the preparation of azilsartan medoxomil
MY161482A (en) Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
MY150980A (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
MX366793B (es) Metodos para preparar oxazolidinonas y composiciones que las contienen.
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2010014566A3 (en) Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
EP2613787A4 (en) PROCESSES FOR THE PREPARATION OF 4- {4- [5 (S) - (AMINOMETHYL) -2-OXO-1,3-OXAZOLIDIN-3-YL] PHENYL} MORPHOLIN-3-ONE
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012046253A3 (en) Process for preparation of n-[2-(7-methoxy-1-naphtityl)ethyl] acetamide and its novel crystalline forms
WO2011024192A3 (en) Novel polymorphs of raltegravir
EP2666765A3 (en) Process for the preparation of substituted 3-(1-amino-2-methyl-pentane-3-yl)phenyl compounds
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2016135747A3 (en) Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
WO2010084514A3 (en) A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
WO2011111971A3 (ko) (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법
WO2009116081A3 (en) An improved process for the preparation of aprepitant
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
WO2009021943A3 (de) Neues herstellverfahren
IL219013A0 (en) Novel solid form of 4-[[(6-chloropyridin-3-yl)methyl(2,2-difluoroethy)amino]furan-2(5h)-one
WO2008015133A3 (en) Process for preparing amidrazones
WO2010140132A8 (en) Process for the preparation of crystalline aprepitant having form i content

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180013805.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11753576

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2091/MUMNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13583492

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11753576

Country of ref document: EP

Kind code of ref document: A2